Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
6 studies found for:    21612468 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed OGX-427 in Castration Resistant Prostate Cancer Patients
Condition: Castration Resistant Prostate Cancer
Interventions: Drug: OGX-427;   Drug: Prednisone
2 Not yet recruiting Study of Abiraterone Acetate Plus ADT Versus APALUTAMIDE Versus Abiraterone and APALUTAMIDE in Patients With Advanced Prostate Cancer With Non-castrate Testosterone Levels
Condition: Prostate Cancer
Interventions: Drug: Apalutamide;   Drug: Abiraterone;   Drug: ADT;   Drug: Prednisone
3 Terminated F-choline PET in Early Response Assessment for Castration Resistant Prostatic Cancer
Condition: Castration-resistant Prostate Cancer
Intervention: Device: F-Choline-PET
4 Recruiting Radiotherapy for Oligometastatic Prostate Cancer
Condition: Oligometastatic Prostate Cancer
Intervention: Radiation: SBRT/SHRT
5 Active, not recruiting Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer
Conditions: Adenocarcinoma of the Prostate;   Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Drug: Alisertib;   Drug: Abiraterone acetate;   Drug: Prednisone
6 Completed
Has Results
Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
Condition: Prostatic Neoplasms
Interventions: Drug: Placebo;   Drug: Abiraterone acetate;   Drug: Prednisone/prednisolone

Study has passed its completion date and status has not been verified in more than two years.